Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
151. |
ECCT/19/10/01 | AMC-099 A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT) |
Principal Investigator(s) 1. ELKANAH ORANGO OMENGE Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTER |
View |
152. |
ECCT/19/07/01 | IMPROVE-2 chemoprevention with monthly IPTp with dihydroartemisinin-piperaquine for malaria in HIV-infected pregnant participants on daily cotrimoxazole in Kenya and Malawi: a multi-centre placebo-controlled trial(IMPROVE-2). |
Principal Investigator(s) 1. Hellen Cherono Barsosio 2. Simon Kariuki Site(s) in Kenya 1. Ahero Sub-County Hospital (Kisumu county) 2. Rabuor Sub-County Hospital (Kisumu county) 3. Akala Sub-County Hospital (Siaya county) |
View |
153. |
ECCT/19/04/02 | NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\" A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
154. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |
155. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
View |